Bruker reported second-quarter 2026 revenue of $838.5 million and a GAAP diluted loss per share of $(0.41), while non-GAAP diluted EPS was $0.49. The company recorded a non-cash goodwill impairment of $134.9 million in Q2, which drove a GAAP operating loss of $(65.3) million versus non-GAAP operating income of $118.5 million. Bruker updated its FY2026 guidance for currency and tax only, expecting revenues of $3.54–$3.57 billion and non-GAAP EPS of $2.10–$2.15.

Financial Highlights

  • Revenue: $838.5 million for the quarter ended June 30, 2026, up 5.2% year-over-year (Q2-25: $797.4M).
  • Gross profit: $416.0 million for Q2-26 with GAAP gross margin of 49.6% (Q2-25 gross profit $357.9M, 44.9%).
  • Operating (loss) / income: GAAP operating loss of $(65.3) million in Q2-26; non-GAAP operating income of $118.5 million and non-GAAP operating margin of 14.1%.
  • Net (loss) income attributable to Bruker common shareholders: GAAP net loss of $(62.9) million for Q2-26; GAAP diluted loss per share $(0.41).
  • Adjusted (Non-GAAP) diluted EPS: $0.49 for Q2-26 (Q2-25 non-GAAP diluted EPS $0.32).

Business Highlights

  • Bruker Scientific Instruments (BSI) bookings grew ~10% organically year-over-year in Q2-26, with BSI book-to-bill above 1.0x.
  • Segment performance: BSI revenue $767.3 million (+4.7% yoy, organic +2.3%); Bruker Energy & Supercon Technologies (BEST) revenue $74.2 million (+11.9% yoy, organic +8.9%).
  • Geographic dynamics: Strong aca/gov bookings in Europe and China; U.S. academic demand remained soft in Q2-26.
  • Company emphasized cost and profitability actions, citing expanded cost savings initiatives contributing to margin expansion and expected continued non-GAAP EPS growth into 2027.
  • Cash flow and balance sheet notes: Cash & equivalents $184.9 million at June 30, 2026; inventories $1,120.1 million; total assets $6,052.9 million and total shareholders' equity $2,400.2 million.

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.